MGMT and neoplasm: Specifically, there appears to be a more pronounced benefit in patients <65 years of age (vs those ≥65 years of age), higher Karnofsky performance score (90-100 vs ≤80), and in patients with MGMT promoter methylation (vs those without MGMT promoter methylation).42 Although relationships with tumor biomarker and genetic status have been suggested, results have been highly inconsistent and should be interpreted cautiously given the heterogeneous and relatively small populations examined.48,55,79,82